Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Gemcitabine and Capecitabine in Resected Pancreatic Cancer
NCT05415917Phase 2Withdrawn
- Sponsor
- Rutgers University
- Start
- Jul 2022
- Primary completion
- Aug 2024
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gemcitabine, capecitabine in pancreatic ductal adenocarcinoma (PDAC), sponsored by Rutgers University. Planned start Jul 2022; status: withdrawn.
02
Drugs
gemcitabinecapecitabine
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05415917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05415917.